1. Breaking New Ground With Migraine Prevention Therapies

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. What Are the Unmet Needs of Patients With Migraine?

6. Underdiagnosis and Undertreatment of Migraine

7. Traditional Migraine Prevention Treatments

8. Traditional Preventive Treatments: Limited Tolerability

9. Patients' Preferences for Migraine Prevention Therapy

10. mAbs Targeting the CGRP Pathway for Migraine Prevention

11. Anti-CGRP mAbs: Reduction in Migraine Days and Disability Score

12. Latest Data on Migraine Prevention Therapies: What Is New and Important?

13. Introduction

14. Phase 3 Trial Design in Episodic Migraine: Example of Erenumab

15. Erenumab in Episodic Migraine: STRIVE

16. Galcanezumab Phase 3 Data in Episodic Migraine: 50% and 75% Responder Rates

17. Fremanezumab Phase 3 Data in Episodic Migraine: Change in Monthly Migraine Days and 50% Responder Rates

18. Eptinezumab Phase 3 Data in Frequent Episodic Migraine: Change in Monthly Migraine Days and 75% Responder Rates

19. Safety of Anti-CGRP mAbs: Similar to Placebo

20. Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

21. Galcanezumab in Patients With Previous Treatment Failure: Episodic and Chronic Migraine Findings

22. Erenumab in Patients With Episodic Migraine and Previous Treatment Failures: LIBERTY

23. Concluding Remarks

24. Monoclonal Antibodies and Their Implications in Treating Migraine

25. Research and Development of mAbs: Rapidly Evolving in Several Therapeutic Areas

26. CGRP and Migraine Pathophysiology

27. Timeline: CGRP and Migraine

28. CGRP in the Body

29. Anti-CGRP mAbs: How Do They Work?

30. Tolerability of Anti-CGRP mAbs

31. Concluding Remarks

32. Additional News and Trends on Migraine Management: What Else the Neurologist Needs to Know

33. Misdiagnosis of Migraine

34. Common Misdiagnoses of Migraine

35. Underuse of Preventive Treatment for Migraine

36. Management Approaches for Migraine

37. Preventive Medication for Migraine

38. Additional Approaches for Migraine Prevention

39. Other Investigational Approaches to Migraine Treatment: PACAP

40. Other Investigational Approaches to Migraine Treatment: Ditans

41. Gepants Under Investigation for Acute Treatment of Migraine

42. Results With Single Pulse TCMS: ESPOUSE

43. Non-Invasive Vagal Nerve Stimulation in Acute Treatment of Migraine Attacks: PRESTO

44. Concluding Remarks

45. Program Conclusions

46. Abbreviations

47. Abbreviations (cont)